CATALYST PHARMACEUTICALS INC's ticker is CPRX and the CUSIP is 14888U101. A total of 233 filers reported holding CATALYST PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.86 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $336,777 | -11.1% | 28,809 | +2.2% | 0.00% | 0.0% |
| Q2 2023 | $378,900 | -20.2% | 28,192 | -1.6% | 0.00% | -25.0% |
| Q1 2023 | $474,967 | -7.4% | 28,647 | +3.9% | 0.00% | -20.0% |
| Q4 2022 | $512,653 | +50.8% | 27,562 | +3.9% | 0.01% | +25.0% |
| Q3 2022 | $340,000 | +82.8% | 26,534 | -0.1% | 0.00% | +100.0% |
| Q2 2022 | $186,000 | -15.5% | 26,548 | +0.3% | 0.00% | 0.0% |
| Q1 2022 | $220,000 | +23.6% | 26,481 | +0.6% | 0.00% | +100.0% |
| Q4 2021 | $178,000 | +25.4% | 26,330 | -1.6% | 0.00% | 0.0% |
| Q3 2021 | $142,000 | -7.8% | 26,748 | -0.2% | 0.00% | 0.0% |
| Q2 2021 | $154,000 | +16.7% | 26,811 | -6.5% | 0.00% | 0.0% |
| Q1 2021 | $132,000 | +38.9% | 28,664 | +0.5% | 0.00% | 0.0% |
| Q4 2020 | $95,000 | +8.0% | 28,526 | -3.8% | 0.00% | 0.0% |
| Q3 2020 | $88,000 | -13.7% | 29,643 | +33.7% | 0.00% | 0.0% |
| Q2 2020 | $102,000 | +21.4% | 22,173 | +1.8% | 0.00% | 0.0% |
| Q1 2020 | $84,000 | – | 21,773 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANAKA CAPITAL MANAGEMENT INC | 148,281 | $1,902,000 | 5.68% |
| GABLES CAPITAL MANAGEMENT INC. | 433,814 | $5,566,000 | 4.46% |
| Quantedge Capital Pte Ltd | 503,700 | $6,462,000 | 1.99% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 4,896,000 | $62,816,000 | 1.25% |
| Lanham O'Dell & Company, Inc. | 20,145 | $258,000 | 0.92% |
| Capital Impact Advisors, LLC | 59,301 | $907,000 | 0.90% |
| SummerHaven Investment Management, LLC | 98,840 | $1,268,000 | 0.88% |
| Yorktown Management & Research Co Inc | 50,000 | $642,000 | 0.83% |
| GLOBEFLEX CAPITAL L P | 304,293 | $3,904,000 | 0.67% |
| AFFINITY INVESTMENT ADVISORS, LLC | 90,864 | $1,166,000 | 0.60% |